ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Baxalta pursues cellular therapy

by Lisa M. Jarvis
March 7, 2016 | APPEARED IN VOLUME 94, ISSUE 10

Baxalta will pay $105 million to genome-editing firm Precision BioSciences as part of a pact to develop off-the-shelf chimeric antigen receptor T-cell (CART) therapies for six cancer targets. The most advanced CART therapies have been highly personalized: Companies reengineer a patient’s own T cells to find and destroy cancer cells. Precision BioSciences’ genome-editing technology allows CARTs to be developed from healthy donors as treatments for multiple patients. The partners expect the first allogeneic CART therapy will enter the clinic late next year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment